Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy
Caroline Lefèbvre(Université de Bordeaux), Julien Mazières(Université Toulouse III - Paul Sabatier), C. Raherisson(Université de Bordeaux), Laura Mezquita(Hospital Clínic de Barcelona), M. Sabatier(Institut universitaire du cancer de Toulouse Oncopole), E. Martin(Institut de Cancérologie de l'Ouest), Lizza Hendriks(Maastricht University), Florent Puisset(Université Toulouse III - Paul Sabatier), Benjamin Besse(Institut Gustave Roussy), Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux), Roberto Ferrara(Vita-Salute San Raffaele University), Anne‐Marie C. Dingemans(Erasmus MC Cancer Institute), Thomas Filleron(Institut universitaire du cancer de Toulouse Oncopole)
Cited by 8
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k